Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01203930 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01203930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01203930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2010
Completion date
June 30, 2016
Enrollment
105 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll)